drugset / Trial / NCT03282396
Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma
Phase 2
Active not recruiting
20 enrolled
M.D. Anderson Cancer Center
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well ibrutinib works in treating participants with untreated high risk smoldering mental cell lymphoma. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2020-06-08
- Primary completion
- 2028-02-28
- Completion
- 2028-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrutinib | Small molecule | — | Oral |